Difficult-to-control secondary hypertension in a patient with history of glioblastoma, and cerebral edema — a case study by Placek, Małgorzata et al.
88 www.journals.viamedica.pl/arterial_hypertension
CASE REPORT
Address for correspondence: Marta Sołtysiak, M.D., Ph.D., Department of Internal Diseases, Hypertension Unit, Municipal Hospital, 
Copernicus PL, ul. Nowe Ogrody 1–6, Gdańsk; e-mail: msoltysiak@copernicus.gda.pl
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles 
and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
Copyright © 2021 Via Medica, ISSN 2449–6170, e-ISSN 2449–6162
Difficult-to-control secondary hypertension 
in a patient with history of glioblastoma, 
and cerebral edema — a case study
Małgorzata Placek*1, Marta Sołtysiak*1, Jacek Drozdowski1, Jacek Wolf2
1Department of Internal Diseases with Hypertension Unit, Copernicus Municipal Hospital, Gdańsk, Poland
2Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland
*both authors equally contributed 
Case report
A 75-year-old female patient with uncontrolled 
high blood pressure, a history of hypertension 
secondary to chronic kidney disease, after unilat-
eral nephrectomy due to cancer (clear cell renal 
cell carcinoma), remaining renal artery stenosis, 
all of which superimposed on long-lasting essen-
tial hypertension, and a suspicion of central ner-
vous system (CNS) glioblastoma, was admitted 
to our Clinic after a convulsive episode. Blood 
pressure (BP) at admission was 254/98 mm Hg 
and the heart rate 38/min. Upon physical exami-
nation a residual left hemiparesis and left sided 
ataxia was evident. Standard electrocardiography 
and heart ultrasonography showed left ventricular 
(LV) hypertrophy and the impaired LV relaxation. 
Laboratory tests were consistent with the diagno-
sis of CKD; additionally, microcytic anemia and 
substantially elevated levels of NT-pro-BNP were 
documented (see Tab. 1). 
24-hour blood pressure monitoring showed mean 
24-h systolic BP at 204 mm Hg and diastolic BP at 
83 mm Hg (range from 156/71 to 239/94 mm Hg). 
Abstract
We report a history of a patient with difficult-to-control high blood pressure, central nervous system mass and several 
comorbidities which altogether made the blood-lowering medication particularly challenging. Patient was diag-
nosed with glioblastoma, renovascular stenosis to a single kidney, and cerebral edema resulting from both cerebral 
tissue mass and exceedingly high systemic blood pressure. In the presented case we faced several contraindications 
to the guideline-recommended treatment with RAAS blockers, beta-blockers, and several diuretic classes which 
were determined by (1) the only remaining kidney’s renal artery stenosis, (2) decreased creatinine clearance and (3) 
reflex bradycardia secondary to cerebral edema. Evidence-based recommendations do not clarify all clinical aspects 
related to emergent high blood pressure because the evidence is sparse; therefore, we found it interesting to share 
our experience.
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CNS magnetic resonance imaging (MRI) revealed 
an extensive edema of vascular origin in the white 
matter of the following areas: right parietal, right 
temporal and right occipital lobes with positive mass 
effect, partial compression of the right lateral ven-
tricle and midline shift up to 8 mm (Fig. 1). Fu-
rosemide and corticosteroids were administered to 
control cerebral edema. Given comorbid CKD and 
renovascular stenosis the choice of suitable and effec-
tive blood-lowering drug combination was challeng-
ing as it was substantially limited to only few drug 
classes. During the hospitalization, blood pressure 
was managed with IV. urapidil (BP-driven dosing), 
supplemented with oral methyldopa (0.5 g  qid), 
clonidine (75 μg tid), nitrendipine (0.02 g bid) and 
doxazosine (0.008 g bid), which facilitated BP con-
trol at mean ambulatory BP level of 160/80 mm Hg. 
A partial resolution of neurological dysfunction was 
evident subsequent to BP lowering. Following in-
terdisciplinary medical consultancy, based on both 
available evidence including advanced neoplasmatic 
disease and unstable clinical condition, the patient 
was disqualified from neuroanesthesia and oncologi-
cal treatment, as well as from renal artery angioplas-
ty. Patient was transferred to palliative care at the 
hospice facility.
Discussion
In the presented case, there were several therapeutic 
challenges including defining the targets for systemic 
BP as well as ensuring the effective BP control. 
According to the current European Societies of 
Hypertension, and Cardiology (ESH-ESC), and 
Polish Society of Hypertension (PTNT) guide-
lines, management of high BP-related emergencies 
is determined by comorbidities and may include 
either the most careful reduction of BP in case 
of acute stroke or immediate substantial reduc-
tion of BP in acute pulmonary edema or aorta 
dissection. In majority of clinical cases of hyper-
tension emergencies and urgencies, a prompt BP 
lowering is required, for a maximum of 25% of 
initial BP within the first hours by means of both 
oral and parenteral antihypertensive drugs [1, 2]. 
There are no large-scale randomized clinical tri-
als evaluating different therapeutic strategies in 
hypertension emergencies, including CNS acute, 
subacute, or chronic failure [2, 3]. Blood pressure, 
intracranial pressure (ICP), and cerebral blood 
flow (CBF) remain in a complex mutual neuro-
physiological relationship mediated by extracranial 
and intracranial factors [4]. CBF autoregulation is 
ensured by complementary mechanisms such as 
metabolic and neurogenic (chemoreceptor- and 
baroreceptor-mediated) and myogenic factors, 
the latter effective only when cerebral perfusion 
pressure (CPP) is maintained and controlled by 
carotid-located baroreceptors [4, 5].
We were not able to precisely define causality 
between CNS mass, and the extent of an increased 
ICP, as high systemic BP could also contribute. 
It was reasonable to deliberate whether high systemic 
BP confer CNS edema, thus blood pressure lowering 
could result in brain edema reduction which might 
Table 1. Clinical and biochemical baseline characteristics
Clinical parameters Value
Office systolic BP [mm Hg] 254
Office diastolic BP [mm Hg] 98











BP — blood pressure; BMI — body mass index; eGFR — estimated glomerular filtration 
rate; NA — sodium; K — potassium; NT-pro-BNP — N-terminal pro b-type natriuretic 
peptide Figure 1. Magnetic resonance imaging of the brain at admission
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translate to CNS dysfunction alleviation. Partial 
withdrawal of the neurological symptoms following 
systemic BP fall actually confirmed our assumption 
(ex juvantibus). In fact, hypertensive encephalopa-
thy, first described by Oppenheimer and Fishberg, 
includes a complex of acute, and more importantly 
potentially reversible, neurological symptoms result-
ing from an increase of systemic blood pressure [6, 
7]. High blood pressure, its’ sudden increase and 
high variability are considered contributory to ce-
rebral perfusion breakdown and blood-brain barrier 
damage with subsequent CNS dysfunction exac-
erbation. Hypertensive encephalopathy is usually 
a multifactorial condition — most often second-
ary to arterial hypertension, but also described in 
the late stage of pregnancy intoxication, hemolytic 
uremic syndrome, thrombotic thrombocytopenic 
purpura, chronic kidney disease, systemic diseases 
and as a consequence of treatment with cyclosporin 
A, calcineurin inhibitors, interferon alpha, or even 
digoxin [8–10]. In the presented case, the main 
cause of ICP increase and cerebral edema was prob-
ably due to glioblastoma, but the contribution of 
renal artery stenosis and secondary uncontrolled 
hypertension could not be excluded, as previously 
described by Sharer et al. [11]
CNS vasoconstriction caused by a rapid BP-rise 
which results in cerebral ischemia due to endothe-
lial cells damage and intra-arterial thrombosis with 
consequent occurrence of cytotoxic edema was con-
firmed by angiography and SPECT-based case stud-
ies [12–15].
Another abnormality, which was not easy to 
explain and address was heightened levels of na-
triuretic peptide (Tab. 1). The possible reason for 
elevated B-type NP include: comorbid heart failure 
(HFpEF), chronic kidney disease, central nervous 
system malignancy itself, and/or hypertensive en-
cephalopathy [16–19].  
Our patient was also diagnosed with long-stand-
ing hypertension. Today, chronic hypertension 
may be easily managed by the combination ther-
apy with RAAS blockers as the core together with 
thiazide/thiazide-like diuretics and/or calcium 
channel blockers as add-ons, preferably in single 
pill combination (SPC). Such drug combination 
especially in SPC formulation is capable of ef-
fectively controlling of roughly 85% hypertensive 
population (beta-blocker may be added based on 
multiple coexisting conditions) [1, 2]. However, 
in the presented case, we faced several contraindi-
cations to the guideline-recommended treatment 
with RAAS blockers, beta-blockers, and several 
diuretics’ classes, i.e.: the only remaining, kidney, 
renal artery stenosis, decreased creatinine clear-
ance and reflex bradycardia secondary to cerebral 
edema. Given that patient was disqualified from 
renal artery angioplasty her hypertension could 
be managed only with less commonly used oral 
agents, which allowed to control BP within lim-
ited extent. 
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